Literature DB >> 20735439

CD200R1 regulates the severity of arthritis but has minimal impact on the adaptive immune response.

E Simelyte1, S Alzabin, I Boudakov, R Williams.   

Abstract

CD200R1 is a member of the immunoglobulin supergene family that is thought to play an inhibitory role in immunity. Previous studies have established the anti-arthritic effect of CD200Fc, an agonist of CD200R1. However, the physiological role played by CD200R1 in arthritis remains to be established. The aims of this study are to assess the contribution of endogenous CD200R1 in regulating the severity of arthritis and to determine its role in shaping the immune response to type II collagen within the context of collagen-induced arthritis, an animal model of rheumatoid arthritis. Arthritis was induced in DBA/1 mice by immunization with type II collagen and the kinetics of expression of CD200R1 and CD200 were monitored by quantitative reverse transcription-polymerase chain reaction. Next, a comparison was made between CD200R1(-/-) and wild-type mice in terms of the progression of collagen-induced arthritis, as well as the B and T cell responses to type II collagen. The expression of both CD200R1 and CD200 was increased after immunization and reached maximal levels at the height of the inflammatory response. In addition, the severity of arthritis was increased significantly in CD200R1(-/-) mice compared to wild-type mice. However, little or no differences were observed between CD200R1(-/-) and wild-type mice in terms of the T or B cell responses to type II collagen. It was concluded that the CD200R1/CD200 pathway is up-regulated in arthritis and plays a significant physiological role in regulating the severity of disease. In contrast, CD200R1 plays a minimal role in shaping the immune response to collagen in this model.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20735439      PMCID: PMC2990942          DOI: 10.1111/j.1365-2249.2010.04227.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules.

Authors:  Reginald Gorczynski; Zhiqi Chen; Yu Kai; Lydia Lee; Simon Wong; Philip A Marsden
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

2.  Molecular mechanisms of CD200 inhibition of mast cell activation.

Authors:  Shuli Zhang; Holly Cherwinski; Jonathon D Sedgwick; Joseph H Phillips
Journal:  J Immunol       Date:  2004-12-01       Impact factor: 5.422

3.  Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis.

Authors:  Cathryn Broderick; Robert M Hoek; John V Forrester; Janet Liversidge; Jonathon D Sedgwick; Andrew D Dick
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  CD200 immunoadhesin suppresses collagen-induced arthritis in mice.

Authors:  R M Gorczynski; Z Chen; K Yu; J Hu
Journal:  Clin Immunol       Date:  2001-12       Impact factor: 3.969

5.  The CD200 receptor is a novel and potent regulator of murine and human mast cell function.

Authors:  Holly M Cherwinski; Craig A Murphy; Barbara L Joyce; Mike E Bigler; Yaoli S Song; Sandra M Zurawski; Mehrdad M Moshrefi; Daniel M Gorman; Kathy L Miller; Shuli Zhang; Jonathan D Sedgwick; Joseph H Phillips
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

6.  Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function.

Authors:  G J Wright; M J Puklavec; A C Willis; R M Hoek; J D Sedgwick; M H Brown; A N Barclay
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

7.  A critical function for CD200 in lung immune homeostasis and the severity of influenza infection.

Authors:  Robert J Snelgrove; John Goulding; Arnaud M Didierlaurent; Daphne Lyonga; Seema Vekaria; Lorna Edwards; Emily Gwyer; Jonathon D Sedgwick; A Neil Barclay; Tracy Hussell
Journal:  Nat Immunol       Date:  2008-07-27       Impact factor: 25.606

8.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

Authors:  R O Williams; M Feldmann; R N Maini
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

Review 9.  CD200 and membrane protein interactions in the control of myeloid cells.

Authors:  A Neil Barclay; Gavin J Wright; Gary Brooke; Marion H Brown
Journal:  Trends Immunol       Date:  2002-06       Impact factor: 16.687

10.  Characterization of the CD200 receptor family in mice and humans and their interactions with CD200.

Authors:  Gavin J Wright; Holly Cherwinski; Mildred Foster-Cuevas; Gary Brooke; Michael J Puklavec; Mike Bigler; Yaoli Song; Maria Jenmalm; Dan Gorman; Terri McClanahan; Man-Ru Liu; Marion H Brown; Jonathon D Sedgwick; Joseph H Phillips; A Neil Barclay
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

View more
  11 in total

1.  Cytomegalovirus e127 protein interacts with the inhibitory CD200 receptor.

Authors:  Mildred Foster-Cuevas; Tina Westerholt; Mohamed Ahmed; Marion H Brown; A Neil Barclay; Sebastian Voigt
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

Review 2.  CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.

Authors:  Jin-Qing Liu; Aiyan Hu; Jianmin Zhu; Jianyu Yu; Fatemeh Talebian; Xue-Feng Bai
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.

Authors:  Jin-Qing Liu; Fatemeh Talebian; Lisha Wu; Zhihao Liu; Ming-Song Li; Laichu Wu; Jianmin Zhu; Joseph Markowitz; William E Carson; Sujit Basu; Xue-Feng Bai
Journal:  J Immunol       Date:  2016-07-06       Impact factor: 5.422

4.  Decreased CD200R expression on monocyte-derived macrophages correlates with Th17/Treg imbalance and disease activity in rheumatoid arthritis patients.

Authors:  Song Gao; Bing Hao; Xu Feng Yang; Wei Qian Chen
Journal:  Inflamm Res       Date:  2014-02-05       Impact factor: 4.575

Review 5.  Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?

Authors:  Michiel van der Vlist; Jurgen Kuball; Timothy R D Radstake; Linde Meyaard
Journal:  Nat Rev Rheumatol       Date:  2016-08-19       Impact factor: 20.543

6.  CD200 positive human mesenchymal stem cells suppress TNF-alpha secretion from CD200 receptor positive macrophage-like cells.

Authors:  Mika Pietilä; Siri Lehtonen; Elina Tuovinen; Kaarina Lähteenmäki; Saara Laitinen; Hannu-Ville Leskelä; Antti Nätynki; Juha Pesälä; Katrina Nordström; Petri Lehenkari
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

7.  CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson's disease.

Authors:  Shi Zhang; Xi-Jin Wang; Li-Peng Tian; Jing Pan; Guo-Qiang Lu; Ying-Jie Zhang; Jian-Qing Ding; Sheng-Di Chen
Journal:  J Neuroinflammation       Date:  2011-11-06       Impact factor: 8.322

8.  Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions.

Authors:  Fatemeh Talebian; Jin-Qing Liu; Zhenzhen Liu; Mazin Khattabi; Yukai He; Ramesh Ganju; Xue-Feng Bai
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

9.  The phenotype of circulating follicular-helper T cells in patients with rheumatoid arthritis defines CD200 as a potential therapeutic target.

Authors:  Aron Chakera; Sophia C Bennett; Olivier Morteau; Paul Bowness; Raashid A Luqmani; Richard J Cornall
Journal:  Clin Dev Immunol       Date:  2012-10-04

Review 10.  A new insight into viral proteins as Immunomodulatory therapeutic agents: KSHV vOX2 a homolog of human CD200 as a potent anti-inflammatory protein.

Authors:  Maryam Mousavinezhad-Moghaddam; Abbas Ali Amin; Houshang Rafatpanah; Seyed Abdol Rahim Rezaee
Journal:  Iran J Basic Med Sci       Date:  2016-01       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.